Abstract
The treatment of uveitis has always been a delicate balancing act of managing complications of the disease and the toxicity of the ensuing therapy. Systemic medications have potential side effects to various organ systems in the body and the inherent risk of infectious complications.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial. Arch Ophthalmol. 1994;112(12):1531–9.
Musch DC, Martin DF, Gordon JF, Davis MD, Kuppermann BD. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group. N Engl J Med. 1997;337(2):83–90.
Sanborn GE, Anand R, Torti RE, et al. Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis. Use of an intravitreal device. Arch Ophthalmol. 1992;110(2):188–95.
Callanan DG, Jaffe GJ, Martin DF, Pearson PA, Comstock TL. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol. 2008;126(9):1191–201.
Goldstein DA, Godfrey DG, Hall A, et al. Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Arch Ophthalmol. 2007;125(11):1478–85.
Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology. 2006;113(6):1020–7.
Williams GA, Haller JA, Kuppermann BD, et al. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol. 2009;147(6):1048–54, 1054.e1.
Bratton ML, He YG, Weakley DR. Dexamethasone intravitreal implant (Ozurdex) for the treatment of pediatric uveitis. J AAPOS. 2014;18(2):110–3.
Cordero-Coma M, Garzo I, Calleja S, Galan E, Franco M, Ruiz de Morales JG. Preoperative cataract surgery use of an intravitreal dexamethasone implant (Ozurdex) in a patient with juvenile idiopathic arthritis and chronic anterior uveitis. J AAPOS. 2013;17(6):632–4.
Kumari N, Parchand S, Kaushik S, Singh R. Intractable glaucoma necessitating dexamethasone implant (Ozurdex) removal and glaucoma surgery in a child with uveitis. BMJ Case Rep. 2013;2013.
Cao JH, Mulvalhill M, Zhang L, Joondeph BC, Dacey MS. Dexamethasone Intravitreal Implant in the treatment of persistent uveitic macular edema in the absence of active inflammation. Ophthalmology 2014.
Tomkins-Netzer O, Taylor SR, Bar A, et al. Treatment with repeat dexamethasone implants results in long-term disease control in eyes with noninfectious uveitis. Ophthalmology 2014.
Malcles A, Janin-Manificat H, Yhuel Y, et al. Anterior chamber migration of intravitreal dexamethasone implant (Ozurdex(R)) in pseudophakic eyes: report of three cases. J Fr Ophtalmol. 2013;36(4):362–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Wang, R. (2017). Surgical Therapy: Dexamethasone Biodegradable Intravitreal Implant (Ozurdex®). In: Papaliodis, G. (eds) Uveitis. Springer, Cham. https://doi.org/10.1007/978-3-319-09126-6_46
Download citation
DOI: https://doi.org/10.1007/978-3-319-09126-6_46
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-09125-9
Online ISBN: 978-3-319-09126-6
eBook Packages: MedicineMedicine (R0)